Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Everest Organics
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 43.29 | 50.75 | 42.67 | 49.45 | 52.51 | 52.62 | 32.45 | 44.05 | 42.05 | 40.93 | 53.81 | 51.00 | 42.59 |
| Expenses + | 45.79 | 48.47 | 40.15 | 46.74 | 49.71 | 49.67 | 36.11 | 40.62 | 38.03 | 37.49 | 49.37 | 45.87 | 39.05 |
| Operating Profit | -2.50 | 2.28 | 2.52 | 2.71 | 2.80 | 2.95 | -3.66 | 3.43 | 4.02 | 3.44 | 4.44 | 5.13 | 3.54 |
| OPM % | -5.78% | 4.49% | 5.91% | 5.48% | 5.33% | 5.61% | -11.28% | 7.79% | 9.56% | 8.40% | 8.25% | 10.06% | 8.31% |
| Other Income + | 5.65 | 0.69 | 0.22 | 0.24 | 0.13 | 0.30 | 0.33 | 0.14 | 0.00 | 0.22 | 0.55 | 0.29 | 0.25 |
| Interest | 0.81 | 0.95 | 1.29 | 1.49 | 1.45 | 1.24 | 1.29 | 1.35 | 1.40 | 1.15 | 1.31 | 1.23 | 1.23 |
| Depreciation | 1.10 | 1.26 | 1.29 | 1.32 | 1.33 | 1.85 | 1.47 | 1.47 | 1.47 | 1.56 | 1.52 | 1.52 | 1.52 |
| Profit before tax | 1.24 | 0.76 | 0.16 | 0.14 | 0.15 | 0.16 | -6.09 | 0.75 | 1.15 | 0.95 | 2.16 | 2.67 | 1.04 |
| Tax % | -21.77% | 85.53% | 75.00% | 78.57% | 93.33% | 62.50% | 0.00% | 1.33% | 0.87% | -206.32% | 35.19% | 56.93% | 65.38% |
| Net Profit + | 1.52 | 0.11 | 0.04 | 0.03 | 0.02 | 0.06 | -6.09 | 0.74 | 1.14 | 2.91 | 1.41 | 1.16 | 0.36 |
| EPS in Rs | 1.90 | 0.14 | 0.05 | 0.04 | 0.02 | 0.08 | -7.61 | 0.92 | 1.42 | 3.00 | 1.45 | 1.19 | 0.37 |
Financials of Everest Organics
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 96 | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 188 |
| Expenses + | 91 | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 172 |
| Operating Profit | 5 | 8 | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 11 | 7 | 17 |
| OPM % | 6% | 7% | 6% | 6% | 6% | 11% | 11% | 13% | 3% | 1% | 6% | 5% | 9% |
| Other Income + | 1 | -0 | -0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | 1 | 1 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 |
| Depreciation | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 |
| Profit before tax | 1 | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 7 |
| Tax % | 21% | 20% | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | 77% | -60% | |
| Net Profit + | 1 | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | -1 | 6 |
| EPS in Rs | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.18 | -1.33 | 6.01 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 7% | 9% | 0% | 0% | 0% | 0% |
Financials of Everest Organics
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 |
| Reserves | -5 | -3 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 | 60 | 63 |
| Borrowings + | 26 | 24 | 28 | 19 | 22 | 21 | 18 | 23 | 39 | 51 | 58 | 48 | 49 |
| Other Liabilities + | 35 | 37 | 42 | 51 | 54 | 60 | 68 | 66 | 92 | 105 | 123 | 107 | 115 |
| Total Liabilities | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 237 |
| Fixed Assets + | 24 | 24 | 27 | 33 | 34 | 38 | 39 | 44 | 49 | 54 | 52 | 50 | 49 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 21 | 23 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 41 | 42 | 47 | 52 | 60 | 68 | 80 | 92 | 121 | 136 | 153 | 152 | 166 |
| Total Assets | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 237 |
Financials of Everest Organics
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1 | 4 | 7 | 10 | 5 | 9 | 10 | 14 | 14 | 18 | 16 | -5 |
| Cash from Investing Activity + | -3 | -3 | -7 | -8 | -4 | -5 | -6 | -12 | -17 | -16 | -13 | -5 |
| Cash from Financing Activity + | 2 | -2 | -0 | -2 | -1 | -3 | -3 | -2 | 2 | -3 | -3 | 16 |
| Net Cash Flow | 0 | -0 | 0 | 0 | -0 | 1 | 0 | -0 | -1 | 0 | 0 | 6 |
| Free Cash Flow | -2 | 1 | 0 | 2 | 1 | 2 | 3 | 7 | -3 | 5 | 3 | -11 |
| CFO/OP | 21% | 52% | 119% | 162% | 64% | 50% | 51% | 59% | 214% | 1,981% | 149% | -76% |
Financials of Everest Organics
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 |
| Inventory Days | 46 | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 166 |
| Days Payable | 184 | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 351 |
| Cash Conversion Cycle | -32 | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 | -11 | 17 |
| Working Capital Days | -43 | -30 | -38 | -50 | -34 | -15 | 7 | 21 | 9 | -12 | -20 | 3 |
| ROCE % | 13% | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% | 6% | 2% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…